Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy ATAI Life Sciences stock
Learn how to easily invest in ATAI Life Sciences stock.
Atai Life Sciences, a Peter Thiel-backed company that produces psychedelic and non-psychedelic mushroom-based therapies for depression and anxiety, is expected to go public. We'll update this page as new information emerges.
How to buy ATAI Life Sciences stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ATAI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
ATAI Life Sciences stock price (NASDAQ: ATAI)Use our graph to track the performance of ATAI stocks over time.
ATAI Life Sciences shares at a glance
|Latest market close||$1.22|
|52-week range||$1.14 - $5.74|
|50-day moving average||$1.78|
|200-day moving average||$3.12|
|Wall St. target price||$13.55|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.29|
Buy ATAI Life Sciences stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy ATAI Life Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ATAI Life Sciences price performance over time
Historical closes compared with the close of $1.22 from 2023-03-17
|1 week (2023-03-09)||N/A|
|1 month (2023-02-16)||-32.60%|
|3 months (2022-12-20)||-59.06%|
|6 months (2022-09-20)||-66.76%|
|1 year (2022-03-18)||-78.41%|
|2 years (2021-03-16)||N/A|
|3 years (2020-03-16)||N/A|
|5 years (2018-03-16)||N/A|
ATAI Life Sciences financials
|Gross profit TTM||$20.4 million|
|Return on assets TTM||-22%|
|Return on equity TTM||-53.78%|
|Market capitalisation||$207.3 million|
TTM: trailing 12 months
ATAI Life Sciences share dividends
We're not expecting ATAI Life Sciences to pay a dividend over the next 12 months.
ATAI Life Sciences overview
Atai Life Sciences N. V. , through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.
ATAI Life Sciences in the news
atai Life Sciences gibt wichtige klinische Pipeline- und Unternehmens-Updates bekannt
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
atai Life Sciences nimmt an der 43. jährlichen Cowen Health Care Conference teil
Frequently asked questionsWhat percentage of ATAI Life Sciences is owned by insiders or institutions?
Currently 9.275% of ATAI Life Sciences shares are held by insiders and 34.869% by institutions. How many people work for ATAI Life Sciences?
Latest data suggests 87 work at ATAI Life Sciences. When does the fiscal year end for ATAI Life Sciences?
ATAI Life Sciences's fiscal year ends in December. Where is ATAI Life Sciences based?
ATAI Life Sciences's address is: Krausenstrasse 9-10, Berlin, Germany, 10117 What is ATAI Life Sciences's ISIN number?
ATAI Life Sciences's international securities identification number is: NL0015000DX5
More guides on Finder
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Ask an Expert